FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would decrease...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Garner, Evan F., Williams, Adele P., Stafman, Laura L., Aye, Jamie M., Mroczek-Musulman, Elizabeth, Moore, Blake P., Stewart, Jerry E., Friedman, Gregory K., Beierle, Elizabeth A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5932040/
https://ncbi.nlm.nih.gov/pubmed/29720672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-25263-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky